AstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of ...

AstraZeneca's experimental breast cancer drug camizestrant, when combined with a cyclin-dependent kinase inhibitor, has shown significant improvement in delaying disease progression in patients with ...

Get Instant Summarized Text (Gist) Cyclin-dependent kinase 2 (CDK2) is identified as a potential target for cancer therapy, particularly in overcoming resistance to CDK4/6 inhibitors used in ...

Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s ...

The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with ...

Equities researchers at StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) in a note issued to investors on Friday. The brokerage set a “sell” ...

(Alliance News) - AstraZeneca PLC on Wednesday said its drug camizestrant significantly delayed disease progression in a phase III trial for advanced hormone receptor-positive breast cancer, ...

Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s (AZN) camizestrant in ...

Results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s (AZN) camizestrant in combination with a ...

Researchers conduct a retrospective, population-based cohort study of adult patients with metastatic breast cancer who underwent genomic profiling at academic institutions.

Verzenio plus Faslodex improved progression-free survival in HR+/HER2– advanced breast cancer after CDK/6i failure, with a ...

Amgen and AstraZeneca have reported outcomes from the WAYPOINT trial of Tezspire for treating chronic rhinosinusitis with ...